New combo therapy aims to tackle colorectal cancer liver spread

NCT ID NCT06848465

Recruiting now Disease control Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether adding low-dose radiation to standard immunotherapy and chemotherapy is safe for people with colorectal cancer that has spread only to the liver. About 9 to 18 participants will receive the combination treatment. The main goal is to check for side effects and see if the approach is feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Low-dose radiotherapy, tislelizumab (immunotherapy), oxaliplatin and capecitabine (chemotherapy)
What this could lead to: If this combination proves safe and feasible, it could point toward a new treatment option for colorectal cancer that has spread only to the liver.
What could go wrong: This is a very early phase 1 trial with only 9-18 participants, so the main goal is safety, not effectiveness. The combination may cause significant side effects and might not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm Lhermitte-Duclos disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER LDRT LIVER METASTASIS

Contacts and locations

Locations

Army Medical Center
RECRUITING

Chongqing, Chongqing Municipality, 400042, China
Daping Hospital, Army Medical University
ACTIVE_NOT_RECRUITING

Chongqing, Chongqing Municipality, 400042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.